Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 30Docetaxel 10Cetuximab 10Trastuzumab 9Paclitaxel 7Nivolumab 6Magnetic Resonance Spectroscopy 6palbociclib 5cemiplimab 5Gemcitabine 5Cyclophosphamide 5Carboplatin 5Capecitabine 5Biopsy 5durvalumab 4atezolizumab 4Surveys and Questionnaires 4Radiotherapy 4Fulvestrant 4Fluorodeoxyglucose F18 4Drug Therapy 4Cisplatin 4selpercatinib 3poly ICLC 3pazopanib 3fludarabine 3avelumab 3Taxes 3Sunitinib 3Specimen Handling 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × vofatamab × Head & Neck × Clear all
NCT05363605 2023-12-19

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Fusion Pharmaceuticals Inc.

Phase 1/2 Terminated
6 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Liver Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡